We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+18.58%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$733M
AUM Growth
-$135M
Cap. Flow
-$230M
Cap. Flow %
-31.36%
Top 10 Hldgs %
42.15%
Holding
113
New
16
Increased
22
Reduced
29
Closed
27

Top Buys

Rank Stock Value
1
ORKA
Oruka Therapeutics
ORKA
+$12M
2
NUVL
Nuvalent
NUVL
+$11.4M
3
ALKS icon
Alkermes
ALKS
+$9.33M
4
ARWR icon
Arrowhead Research
ARWR
+$6.71M
5
VRDN icon
Viridian Therapeutics
VRDN
+$6.13M

Top Sells

Rank Stock Value
1
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$20.4M
2
ONC
BeOne Medicines Ltd
ONC
+$13.5M
3
CLDX icon
Celldex Therapeutics
CLDX
+$13.4M
4
MORF
Morphic Holding, Inc. Common Stock
MORF
+$8.54M
5
APGE icon
Apogee Therapeutics
APGE
+$8.25M

Sector Composition

Rank Sector Weight
1 Healthcare 81.54%
2 Financials 0.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TNGX icon
101
Tango Therapeutics
TNGX
$4.48B
– –
-150,274
Closed -$1.29M
TWST icon
102
CALL
Twist Bioscience
TWST
$5.45B
– –
-45,000
Closed -$2.22M
VIR icon
103
Vir Biotechnology
VIR
$1.56B
– –
-200,000
Closed -$1.78M
XBI icon
104
State Street SPDR S&P Biotech ETF
XBI
$10.1B
– –
-37,550
Closed -$3.48M
ZYME icon
105
Zymeworks
ZYME
$1.75B
– –
-191,127
Closed -$1.63M
MORF
106
DELISTED
Morphic Holding, Inc. Common Stock
MORF
– –
-250,573
Closed -$8.54M
CERE
107
CALL
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
– –
-250,000
Closed -$10.2M
CERE
108
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
– –
-500,000
Closed -$20.4M
ARYD
109
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
– –
-133,500
Closed -$1.53M
1 2 3 4
5

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q3 2024 Portfolio in Review

As of Q3 2024, Affinity Asset Advisors held 113 positions worth $733M, down 16% from $868M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Affinity Asset Advisors withdrew a net $230M in Q3 2024, closing 27 positions and reducing 29 holdings. Its most notable exit was Cerevel Therapeutics Holdings, Inc. Common Stock, an estimated $20.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 65% a quarter earlier, followed by Financials.

Against the trend, Affinity Asset Advisors opened a new position in Arvinas worth $5.54M.

  • Affinity Asset Advisors's largest Q3 2024 buy was Arvinas: 225,000 shares worth $5.54M.
  • Affinity Asset Advisors added most to Oruka Therapeutics in Q3 2024, an estimated $12M increase.
  • Affinity Asset Advisors's biggest Q3 2024 reduction was BeOne Medicines Ltd, cutting an estimated $13.5M.
  • Affinity Asset Advisors fully exited Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2024, selling an estimated $20.4M.
  • Affinity Asset Advisors's ten largest holdings make up 42% of its $733M portfolio in Q3 2024.
  • Affinity Asset Advisors opened 16 new positions and closed 27 in Q3 2024.
  • Affinity Asset Advisors's portfolio value fell 16% quarter-over-quarter to $733M.

Based on Affinity Asset Advisors's 13F filing for Q3 2024, filed 13 Nov 2024.